» Articles » PMID: 20145172

Frequent Downregulation of MiR-34 Family in Human Ovarian Cancers

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2010 Feb 11
PMID 20145172
Citations 167
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The miR-34 family is directly transactivated by tumor suppressor p53, which is frequently mutated in human epithelial ovarian cancer (EOC). We hypothesized that miR-34 expression would be decreased in EOC and that reconstituted miR-34 expression might reduce cell proliferation and invasion of EOC cells.

Experimental Designs: miR-34 expression was determined by quantitative reverse transcription-PCR and in situ hybridization in a panel of 83 human EOC samples. Functional characterization of miR-34 was accomplished by reconstitution of miR-34 expression in EOC cells with synthetic pre-miR molecules followed by determining changes in proliferation, apoptosis, and invasion.

Results: miR-34a expression is decreased in 100%, and miR-34b*/c in 72%, of EOC with p53 mutation, whereas miR-34a is also downregulated in 93% of tumors with wild-type p53. Furthermore, expression of miR-34b*/c is significantly reduced in stage IV tumors compared with stage III (P = 0.0171 and P = 0.0029, respectively). Additionally, we observed promoter methylation and copy number variations at mir-34. In situ hybridization showed that miR-34a expression is inversely correlated with MET immunohistochemical staining, consistent with translational inhibition by miR-34a. Finally, miR-34 reconstitution experiments in p53 mutant EOC cells resulted in reduced proliferation, motility, and invasion, the latter of which was dependent on MET expression.

Conclusions: Our work suggests that miR-34 family plays an important role in EOC pathogenesis and reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages. Part of miR-34 effects on motility and invasion may be explained by regulation of MET, which is frequently overexpressed in EOC.

Citing Articles

Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.

Phuong D, Pirtz M, Ralston C, Cosgrove B, Schimenti J, Flesken-Nikitin A Cancers (Basel). 2025; 17(4).

PMID: 40002199 PMC: 11852459. DOI: 10.3390/cancers17040604.


Engineered mesenchymal stem/stromal cells against cancer.

Shi Y, Zhang J, Li Y, Feng C, Shao C, Shi Y Cell Death Dis. 2025; 16(1):113.

PMID: 39971901 PMC: 11839947. DOI: 10.1038/s41419-025-07443-0.


Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin.

Poma P, Rigogliuso S, Labbozzetta M, Nicosia A, Costa S, Ragusa M Int J Mol Sci. 2025; 25(24.

PMID: 39769180 PMC: 11679585. DOI: 10.3390/ijms252413416.


miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.

Wang X, Woo H, Wei M, Gibson S, Miranda M, Rush D Sci Rep. 2024; 14(1):29937.

PMID: 39622842 PMC: 11611913. DOI: 10.1038/s41598-024-80173-z.


Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma.

Flesken-Nikitin A, Ralston C, Fu D, De Micheli A, Phuong D, Harlan B Nat Commun. 2024; 15(1):8641.

PMID: 39366996 PMC: 11452611. DOI: 10.1038/s41467-024-52984-1.


References
1.
Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

2.
Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao D . Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29(2):218-24. DOI: 10.1097/01.pas.0000146025.91953.8d. View

3.
Corney D, Flesken-Nikitin A, Godwin A, Wang W, Nikitin A . MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007; 67(18):8433-8. DOI: 10.1158/0008-5472.CAN-07-1585. View

4.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

5.
Merritt W, Lin Y, Han L, Kamat A, Spannuth W, Schmandt R . Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008; 359(25):2641-50. PMC: 2710981. DOI: 10.1056/NEJMoa0803785. View